Saxagliptin and risk of heart failure hospitalization: Concern or miscalculation?

International Journal of Cardiology

Volumn 220, Issue , 2016, Pages 573-574

  Cebrián Cuenca, Ana María ^a   Orozco Beltrán, Domingo ^b   Navarro Pérez, Jorge ^c   Franch Nadal, Josep ^d   Núñez Villota, Julio ^c   Consuegra Sánchez, Luciano ^e  

^a Centro de Salud San Antón   (Spain)

^b Centro de Salud Cabo Huertas   (Spain)

^c Instituto Universitario IVI INCLIVA   (Spain)

^d Centro de Salud Raval Sud   (Spain)

^e Hospital Santa Lucia   (Spain)

Author keywords

Heart failure; Multiplicity; Saxagliptin

Indexed keywords

NATRIURETIC FACTOR; SAXAGLIPTIN; ADAMANTANE; DIPEPTIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR;

ANGINA PECTORIS; ARTICLE; BRAIN ISCHEMIA; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL STUDY; CUMULATIVE HOSPITALIZATION; DISEASE ASSOCIATION; FOOD AND DRUG ADMINISTRATION; HEART FAILURE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; MEDICAL HISTORY; NON FATAL ISCHEMIC STROKE; NON FATAL MYOCARDIAL INFARCTION; PRIORITY JOURNAL; SAXAGLIPTIN ASSESSMENT OF VASCULAR OUTCOMES RECORDED IN PATIENTS WITH DIABETES MELLITUS THROMBOLYSIS IN MYOCARDIAL INFARCTION; STATISTICAL SIGNIFICANCE; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; TRENDS;

ADAMANTANE; DIPEPTIDES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HEART FAILURE; HOSPITALIZATION; HUMANS;

EID: 84978114954     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2016.06.269     Document Type: Article

References (6)

1. [1] Pocock, S.J., McMurray, J.J., Collier, T.J., Statistical controversies in reporting of clinical trials: part 2 of a 4-part series on statistics for clinical trials. J. Am. Coll. Cardiol. 66 (2015), 2648–2662.
2. [2] Scirica, B.M., Bhatt, D.L., Braunwald, E., et al. SAVOR-TIMI 53 steering committee and investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N. Engl. J. Med. 369:14 (2013), 1317–1326.
3. [3] Scirica, B.M., Braunwald, E., Raz, I., et al. SAVOR-TIMI 53 steering committee and investigators. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation 130 (2014), 1579–1588.
4. [4] Scirica, B.M., Bhatt, D.L., Braunwald, E., et al. The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 study. Am. Heart J. 162:5 (2011), 818–825.
5. [5] Ghosal, S., Sinha, B., Gliptins and cardiovascular outcomes: a comparative and critical analysis after TECOS. J. Diabetes. Res., 2016, 2016, 1643496.
6. [6] Fu, A.Z., Johnston, S.S., Ghannam, A., et al. Association between hospitalization for heart failure and dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: an observational study. Diabetes Care, 2016 Jan 6 (pii: dc150764. Epub ahead of print).